

Senate
Study
Bill
1073
-
Introduced


SENATE/HOUSE
FILE
_____


BY
(PROPOSED
BOARD
OF
PHARMACY


BILL)


A
BILL
FOR


An
Act
relating
to
the
Iowa
prescription
monitoring
program
and
1


making
penalties
applicable.
2


BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
3


TLSB
1267DP
(2)
87


tr/nh/rh



S.F.
_____
H.F.
_____


Section
1.
Section
124.551,
subsection
2,
Code
2017,
is
1


amended
to
read
as
follows:
2


2.
The
program
shall
collect
from
pharmacies
dispensing
3


information
for
controlled
substances
identified
pursuant
to
4


section
124.554,
subsection
1
,
paragraph
“g”
.
The
information
5


collected
shall
be
used
by
prescribing
practitioners
and
6


pharmacists
on
a
need-to-know
basis
for
purposes
of
improving
7


patient
health
care
by
facilitating
early
identification
of
8


patients
who
may
be
at
risk
for
addiction,
or
who
may
be
using,
9


abusing,
or
diverting
drugs


controlled
substances
for
unlawful
10


or
otherwise
unauthorized
purposes
at
risk
to
themselves
and
11


others,
or
who
may
be
appropriately
using
controlled
substances
12


lawfully
prescribed
for
them
but
unknown
to
the
practitioner.
13


Sec.
2.
Section
124.552,
subsection
1,
unnumbered
paragraph
14


1,
Code
2017,
is
amended
to
read
as
follows:
15


Each


Unless
otherwise
prohibited
by
federal
or
state
law,
16


each
licensed
pharmacy
that
dispenses
controlled
substances
17


identified
pursuant
to
section
124.554,
subsection
1
,
paragraph
18


“g”
,
to
patients
in
the
state
,
and


;
each
licensed
pharmacy
19


located
in
the
state
that
dispenses
such
controlled
substances
20


identified
pursuant
to
section
124.554,
subsection
1
,
21


paragraph
“g”
,
to
patients
inside
or
outside
the
state,
unless
22


specifically
excepted
in
this
section
or
by
rule
,


;
and
each
23


prescribing
practitioner
furnishing,
dispensing,
or
supplying
24


controlled
substances
to
the
prescribing
practitioner’s
25


patient,
shall
submit
the
following
prescription
information
26


to
the
program:
27


Sec.
3.
Section
124.552,
subsection
1,
paragraph
a,
Code
28


2017,
is
amended
to
read
as
follows:
29


a.
Pharmacy
identification
,
if
applicable


.
30


Sec.
4.
Section
124.552,
subsections
3
and
4,
Code
2017,
are
31


amended
to
read
as
follows:
32


3.
Information
shall
be
timely
transmitted
as
designated
by
33


the
board
and
advisory
council
by
rule,
unless
the
board
grants
34


an
extension.
The
board
may
grant
an
extension
if
either
of
35


-1-


LSB
1267DP
(2)
87


tr/nh/rh
1/
7
















S.F.
_____
H.F.
_____


the
following
occurs:
1


a.
The
pharmacy
or
prescribing
practitioner


suffers
2


a
mechanical
or
electronic
failure,
or
cannot
meet
the
3


deadline
established
by
the
board
for
other
reasons
beyond
the
4


pharmacy’s
or
prescribing
practitioner’s


control.
5


b.
The
board
is
unable
to
receive
electronic
submissions.
6


4.
This
section
shall
not
apply
to
a
prescribing


7


practitioner
furnishing,
dispensing,
supplying,
or
8


administering
drugs
to
the
prescribing
practitioner’s
patient,


9


or
to
dispensing
by
a
licensed
pharmacy
for
the
purposes
of
10


inpatient
hospital
care,
inpatient
hospice
care,
or
long-term
11


residential
facility
patient
care.
12


Sec.
5.
Section
124.553,
subsection
1,
Code
2017,
is
amended
13


by
adding
the
following
new
paragraph:
14


NEW
PARAGRAPH


.
f.
By
targeted
distribution
of
unsolicited
15


reports,
a
prescribing
practitioner
or
pharmacist
who
has
been
16


involved
in
authorizing
or
dispensing
controlled
substances
17


to
a
patient
who
has
been
identified
by
the
board,
based
on
18


thresholds
or
criteria
established
by
the
board
by
rule,
as
19


an
at-risk
patient
who
may
be
abusing
or
misusing
controlled
20


substances
or
who
may
be
in
jeopardy
of
overdose
or
addiction
21


to
controlled
substances.
22


Sec.
6.
Section
124.553,
subsections
2,
3,
and
8,
Code
2017,
23


are
amended
to
read
as
follows:
24


2.
The
board
shall
maintain
a
record
of
each
person
that
25


requests
information
from
the
program
and
of
all
unsolicited


26


reports
distributed
as
provided
in
subsection
1,
paragraph
27


“f”


.
Pursuant
to
rules
adopted
by
the
board
and
advisory
28


council
under
section
124.554
,
the
board
may
use
the
records
29


to
document
and
report
statistical
information,
and
may
30


provide
program
information
for
statistical,
public
research,
31


public
policy,
or
educational
purposes,
after
removing
32


personal
identifying
information
of
a
patient,
prescribing
33


practitioner,
dispenser,
or
other
person
who
is
identified
in
34


the
information.


35


-2-


LSB
1267DP
(2)
87


tr/nh/rh
2/
7













S.F.
_____
H.F.
_____


3.
Information
contained
in
the
program
and
any
information
1


obtained
from
it,
and
information
contained
in
the
records
of
2


requests
for
information
from
the
program
and
of
unsolicited


3


reports
distributed
to
prescribing
practitioners
and
4


dispensing
pharmacists


,
is
privileged
and
strictly
confidential
5


information.
Such
information
is
a
confidential
public
record
6


pursuant
to
section
22.7
,
and
is
not
subject
to
discovery,
7


subpoena,
or
other
means
of
legal
compulsion
for
release
except
8


as
provided
in
this
division
.
Information
from
the
program
9


shall
not
be
released,
shared
with
an
agency
or
institution,
or
10


made
public
except
as
provided
in
this
division
.
11


8.
The
board
may
enter
into
an
agreement
with
a
prescription
12


database
or
monitoring
program
operated
in
a
state
bordering


13


this
state
or
in
the
state
of
Kansas


any
state
for
the
mutual
14


exchange
of
information.
Any
agreement
entered
into
pursuant
15


to
this
subsection
shall
specify
that
all
the
information
16


exchanged
pursuant
to
the
agreement
shall
be
used
and
17


disseminated
in
accordance
with
the
laws
of
this
state.
18


Sec.
7.
Section
124.554,
Code
2017,
is
amended
to
read
as
19


follows:
20


124.554
Rules
and
reporting.
21


1.
The
board
and
advisory
council
shall
jointly
adopt
22


rules
in
accordance
with
chapter
17A
to
carry
out
the
purposes
23


of,
and
to
enforce
the
provisions
of,
this
division
.
The
24


rules
shall
include
but
not
be
limited
to
the
development
of
25


procedures
relating
to:
26


a.
Identifying
each
patient
about
whom
information
is
27


entered
into
the
program.
28


b.
An
electronic
format
for
the
submission
of
information
29


from
pharmacies
and
prescribing
practitioners


.
30


c.
A
waiver
to
submit
information
in
another
format
for
31


a
pharmacy
or
prescribing
practitioner


unable
to
submit
32


information
electronically.
33


d.
An
application
by
a
pharmacy
or
prescribing
practitioner


34


for
an
extension
of
time
for
transmitting
information
to
the
35


-3-


LSB
1267DP
(2)
87


tr/nh/rh
3/
7












S.F.
_____
H.F.
_____


program.
1


e.
The
submission
by
an
authorized
requestor
of
a
request
2


for
information
and
a
procedure
for
the
verification
of
the
3


identity
of
the
requestor.
4


f.
Use
by
the
board
or
advisory
council
of
the
program
5


request
records
required
by
section
124.553,
subsection
2
,
to
6


document
and
report
statistical
information.
7


g.
Including
all
schedule
II
,
schedule
III,
and
schedule


8


IV


controlled
substances
and
those
substances
in
schedules
9


III
and
IV
that
the
advisory
council
and
board
determine
can
10


be
addictive
or
fatal
if
not
taken
under
the
proper
care
and


11


direction
of
a
prescribing
practitioner
schedule
V
controlled
12


substances
except
when
dispensed
by
a
pharmacist
without
a
13


prescription


.
14


h.
Access
by
a
pharmacist
or
prescribing
practitioner
to
15


information
in
the
program
pursuant
to
a
written
agreement
with
16


the
board
and
advisory
council
.
17


i.
The
correction
or
deletion
of
erroneous
information
in
18


the
program.
19


j.


The
establishment
of
thresholds
or
other
criteria
or
20


measures
to
be
used
in
identifying
an
at-risk
patient
as


21


provided
in
section
124.553,
subsection
1,
paragraph
“f”
,
and
22


the
targeted
distribution
of
unsolicited
reports
suggesting


23


review
of
the
patient’s
prescription
history.
24


2.
Beginning
January
1,
2007
15,
2018
,
and
annually
by
25


January
1
15
thereafter,
the
board
and
advisory
council
shall
26


present
to
the
general
assembly
and
the
governor
a
report
27


prepared
consistent
with
section
124.555,
subsection
3
,
28


paragraph
“d”
,
which
shall
include
but
not
be
limited
to
the
29


following:
30


a.
The
cost
to
the
state
of
implementing
and
maintaining
the
31


program.
32


b.
Information
from
pharmacies,
prescribing
practitioners,
33


the
board,
the
advisory
council,
and
others
regarding
the
34


benefits
or
detriments
of
the
program.
35


-4-


LSB
1267DP
(2)
87


tr/nh/rh
4/
7



























S.F.
_____
H.F.
_____


c.
Information
from
pharmacies,
prescribing
practitioners,
1


the
board,
the
advisory
council,
and
others
regarding
the
2


board’s
effectiveness
in
providing
information
from
the
3


program.
4


Sec.
8.
Section
124.555,
subsection
2,
Code
2017,
is
amended
5


to
read
as
follows:
6


2.
The
council
shall
advance
the
goals
of
the
program,
7


which
include
identification
of
misuse
and
diversion
of
8


controlled
substances
identified
pursuant
to
section
124.554,
9


subsection
1
,
paragraph
“g”
,
reduction
of
drug
overdoses
and


10


deaths
attributable
to
prescription
drug
use
and
abuse,


and
11


enhancement
of
the
quality
of
health
care
delivery
in
this
12


state.
13


Sec.
9.
Section
124.558,
subsection
1,
Code
2017,
is
amended
14


to
read
as
follows:
15


1.
Failure
to
comply
with
requirements.
A
pharmacist,
16


pharmacy,
prescribing
practitioner,
or
agent
of
a
pharmacist
or
17


prescribing
practitioner
who
knowingly
fails
to
comply
with
the
18


confidentiality
requirements
of
this
division
or
who
delegates
19


program
information
access
to
another
individual
except
as
20


provided
in
section
124.553
,
is
subject
to
disciplinary
action
21


by
the
appropriate
professional
licensing
board.
A
prescribing


22


practitioner,


pharmacist
,
or
pharmacy
that
knowingly
fails
to
23


comply
with
other
requirements
of
this
division
is
subject
to
24


disciplinary
action
by
the
board.
Each
licensing
board
may
25


adopt
rules
in
accordance
with
chapter
17A
to
implement
the
26


provisions
of
this
section
.
27


EXPLANATION
28


The
inclusion
of
this
explanation
does
not
constitute
agreement
with
29


the
explanation’s
substance
by
the
members
of
the
general
assembly.
30


This
bill
adds
dispensing
prescribers,
unless
otherwise
31


prohibited
by
federal
or
state
law,
to
those
persons
required
32


to
submit
to
the
Iowa
prescription
monitoring
program
any
33


reportable
controlled
substances
dispensed
or
distributed
to
34


patients
in
this
state.
Dispensing
prescribers
are
added
35


-5-


LSB
1267DP
(2)
87


tr/nh/rh
5/
7








S.F.
_____
H.F.
_____


to
respective
Code
provisions
relating
to
extensions
of
1


time
to
submit
required
records,
the
required
form
of
record
2


submission,
and
penalties
for
failing
to
submit
required
3


records
to
the
Iowa
prescription
monitoring
program.
4


The
bill
authorizes
the
board
of
pharmacy
and
the
Iowa
5


prescription
monitoring
program
advisory
council
to
establish
6


criteria
for
the
identification
of
patients
whose
use
of
7


controlled
substances
may
raise
concerns
about
the
safety
of
8


the
patients’
drug
regimens
and
use
patterns
for
the
purpose
9


of
communicating
those
concerns
with
the
prescribers
and
10


pharmacists
involved
in
the
patients’
care.
11


The
bill
permits
the
board
to
interconnect
with
any
other
12


state
prescription
monitoring
program
for
the
sharing
of
13


patient
prescription
records
on
the
condition
that
the
other
14


state
prescription
monitoring
program
agrees
to
comply
with
15


the
laws
and
rules
of
this
state
regarding
the
access
to,
16


distribution
of,
and
use
of
Iowa
prescription
monitoring
17


program
information
and
data.
The
bill
also
authorizes
the
18


collection
of
dispensing
records
for
all
schedule
II,
III,
19


IV,
and
V
controlled
substances
except
when
the
schedule
V
20


controlled
substance
is
dispensed
by
a
pharmacist
without
a
21


prescription.
22


The
bill
adds
to
the
goals
of
the
program
the
reduction
of
23


overdoses
and
deaths
as
a
result
of
prescription
controlled
24


substance
use
and
abuse.
The
bill
changes
the
due
date
for
25


annual
reports
to
the
governor
and
the
legislature
regarding
26


the
program
from
January
1
to
January
15.
27


A
pharmacist,
pharmacy,
prescribing
practitioner,
or
agent
28


of
a
pharmacist
or
prescribing
practitioner
who
knowingly
fails
29


to
comply
with
the
confidentiality
requirements
of
the
bill
or
30


who
delegates
program
information
access
to
another
individual
31


except
as
provided
in
Code
section
124.553
is
subject
to
32


disciplinary
action
by
the
appropriate
professional
licensing
33


board.
A
pharmacist
or
pharmacy
that
knowingly
fails
to
comply
34


with
other
requirements
of
the
bill
is
subject
to
disciplinary
35


-6-


LSB
1267DP
(2)
87


tr/nh/rh
6/
7



S.F.
_____
H.F.
_____


action
by
the
board.
A
person
who
intentionally
or
knowingly
1


accesses,
uses,
or
discloses
program
information
in
violation
2


of
the
bill,
unless
otherwise
authorized
by
law,
is
guilty
of
a
3


class
“D”
felony.
4


-7-


LSB
1267DP
(2)
87


tr/nh/rh
7/
7

